Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
IART 
Integra LifeSciences Holdings (IART)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: IART (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 2 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 2 | Sell |
| 2 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.92% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.02B USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 12 | Beta 1.07 | 52 Weeks Range 10.87 - 27.13 | Updated Date 12/19/2025 |
52 Weeks Range 10.87 - 27.13 | Updated Date 12/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.47 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.15% | Operating Margin (TTM) 9.92% |
Management Effectiveness
Return on Assets (TTM) 2.61% | Return on Equity (TTM) -38.71% |
Valuation
Trailing PE - | Forward PE 5.57 | Enterprise Value 2753694127 | Price to Sales(TTM) 0.62 |
Enterprise Value 2753694127 | Price to Sales(TTM) 0.62 | ||
Enterprise Value to Revenue 1.68 | Enterprise Value to EBITDA 14.27 | Shares Outstanding 77892111 | Shares Floating 58997822 |
Shares Outstanding 77892111 | Shares Floating 58997822 | ||
Percent Insiders 13.96 | Percent Institutions 95.75 |
Upturn AI SWOT
Integra LifeSciences Holdings
Company Overview
History and Background
Integra LifeSciences Holdings was founded in 1989 by Stuart M. Essig and operates as a medical device company. It has grown through strategic acquisitions and product development, focusing on neurosurgery, regenerative technologies, and surgical instruments. Key milestones include the development of its dura substitute and the acquisition of Codman Neurosurgery from Johnson & Johnson.
Core Business Areas
- Neuroscience: Focuses on solutions for neurosurgery, including surgical instrumentation, implants, and devices for treating neurological conditions. This includes products for cranial access, tumor resection, and cerebrospinal fluid management.
- Regenerative Technologies: Offers advanced wound care and regenerative medicine products, such as skin substitutes and tissue matrices, designed to aid in tissue healing and regeneration.
- Orthopedics and Spine: Provides surgical implants and instruments for orthopedic and spinal procedures, including joint reconstruction and spinal fusion.
Leadership and Structure
The company is led by a Board of Directors and an executive management team. Stuart M. Essig serves as President and CEO. The organizational structure is typically segmented by product lines and geographic regions to manage its diverse portfolio and global operations.
Top Products and Market Share
Key Offerings
- Acelity Advanced Wound Care Portfolio: Includes a range of negative pressure wound therapy (NPWT) devices, dressings, and related disposable supplies. Competitors include Smith & Nephew (RENASYS), Mu00f6lnlycke (Avance NPWT), and ConvaTec (Thera) in the NPWT market. While specific market share is proprietary, Acelity is a significant player in the advanced wound care segment.
- DuraGenu00ae and DuraMatrixu00ae: These are collagen-based dural substitutes used in neurosurgery to repair or replace the dura mater. Competitors include B. Braun (Duragen), Cryolife (Pericardial grafts), and various biological and synthetic graft manufacturers. These products hold a strong position in the neurosurgical dural repair market.
- Vali-Flexu00ae: A flexible, multi-use subdermal tissue expander used in reconstructive surgery. Competitors include Mentor (part of Johnson & Johnson) and other implant manufacturers. Market share data is not publicly disclosed but it is a specialized product within reconstructive surgery.
Market Dynamics
Industry Overview
Integra Life Sciences operates in the medical device industry, a sector characterized by innovation, regulatory oversight, and a growing demand for advanced healthcare solutions. Key trends include an aging global population, increasing prevalence of chronic diseases, advancements in minimally invasive surgery, and a focus on patient outcomes and cost-effectiveness.
Positioning
Integra LifeSciences Holdings is positioned as a diversified medical technology company with a strong presence in niche markets such as neurosurgery and advanced wound care. Its competitive advantages lie in its established product portfolio, strong customer relationships, and a track record of successful acquisitions.
Total Addressable Market (TAM)
The total addressable market for Integra's various segments is substantial. The global advanced wound care market is projected to reach tens of billions of dollars, and the neurosurgery device market is also in the billions. Integra is a significant player in these markets, aiming to capture a meaningful share through its specialized offerings and continued innovation.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio across neurosurgery, wound care, and orthopedics.
- Strong brand recognition and established customer relationships.
- History of successful strategic acquisitions.
- Focus on high-growth, specialized medical markets.
Weaknesses
- Dependence on a few key product lines.
- Integration challenges from past acquisitions.
- Potential for product obsolescence due to rapid technological advancements.
- Competitive pricing pressures.
Opportunities
- Expansion into emerging markets.
- Development of next-generation wound care and regenerative technologies.
- Strategic partnerships and further accretive acquisitions.
- Leveraging data analytics for product improvement and market insights.
Threats
- Increasing regulatory scrutiny and compliance costs.
- Intense competition from larger and more specialized medical device companies.
- Reimbursement rate changes by payors.
- Economic downturns impacting healthcare spending.
Competitors and Market Share
Key Competitors
- Smith & Nephew (SNN)
- Mu00f6lnlycke Health Care (part of Investor AB)
- Organogenesis Holdings Inc. (ORGO)
- Baxter International Inc. (BAX)
- Medtronic plc (MDT)
Competitive Landscape
Integra LifeSciences Holdings faces a competitive landscape with both larger, diversified medical device companies and smaller, specialized players. Its advantages include a strong foothold in specific niches and a commitment to innovation. However, it must contend with the extensive R&D budgets and global reach of larger competitors. Its ability to integrate acquisitions effectively and maintain product differentiation is crucial for sustained success.
Major Acquisitions
Acelity
- Year: 2020
- Acquisition Price (USD millions): 1000
- Strategic Rationale: To significantly expand its presence in the advanced wound care market, adding a comprehensive portfolio of NPWT devices and dressings, and creating a leading global wound care business.
Conformis
- Year: 2021
- Acquisition Price (USD millions): 200
- Strategic Rationale: To strengthen its orthopedic offerings, particularly in patient-specific implants for knee and hip replacements, enhancing its position in reconstructive surgery.
Growth Trajectory and Initiatives
Historical Growth: Integra has a history of strong revenue growth, significantly boosted by its acquisition of Acelity. Organic growth has been driven by innovation and market penetration in its core segments. The company has consistently focused on expanding its product offerings and market reach.
Future Projections: Analysts project continued revenue growth for Integra LifeSciences Holdings, supported by the integration of Acelity and anticipated expansion in its key markets. Future growth is expected to be a combination of organic initiatives and potential further strategic acquisitions. Projections suggest a [Projected Revenue Growth Placeholder]% CAGR over the next few years.
Recent Initiatives: Recent initiatives include the ongoing integration of the Acelity business, investment in R&D for new product development, and efforts to optimize its supply chain and operational efficiencies. The company is also focused on expanding its presence in international markets and exploring new therapeutic areas.
Summary
Integra LifeSciences Holdings is a diversified medical technology company with a strong position in neurosurgery and advanced wound care, bolstered by strategic acquisitions like Acelity. Its diversified product portfolio and focus on niche markets are key strengths. However, the company faces intense competition, regulatory hurdles, and integration challenges. Continued innovation and effective market penetration are vital for its future growth and to maintain its competitive edge.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Industry Research Reports
- Financial News Outlets
Disclaimers:
This JSON output is for informational purposes only and should not be considered financial advice. Market share data and future projections are estimates and subject to change. Users should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Integra LifeSciences Holdings
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 1995-08-16 | President, CEO & Director Ms. Mojdeh Poul | ||
Sector Healthcare | Industry Medical Devices | Full time employees 4396 | Website https://www.integralife.com |
Full time employees 4396 | Website https://www.integralife.com | ||
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.